Moderna"s Quebec Facility Approved to Produce mRNA Vaccines by 2025

Moderna's manufacturing facility in Laval, Quebec, has received a Drug Establishment License from Health Canada, marking a significant step towards domestic production of mRNA vaccines. This certification confirms that the facility meets safety and quality standards, allowing it to produce drug substances. The site is set to begin manufacturing a range of mRNA vaccines, including those for COVID-19, respiratory syncytial virus (RSV), and seasonal influenza, pending Health Canada's approval by 2025. The achievement is part of Moderna's strategic partnership with the Government of Canada, aimed at enhancing the country's pandemic preparedness and ensuring a reliable supply of vaccines. Stéphane Bancel, CEO of Moderna, emphasized the importance of this milestone in establishing certified mRNA manufacturing capabilities outside the U.S. This facility will play a crucial role in supporting the national supply of vital respiratory vaccines. In addition to the Laval site, Moderna is expanding its manufacturing footprint globally, with existing facilities in the U.S. and new sites under construction in Australia and the U.K. The company is also responding to the evolving needs for updated vaccines, as evidenced by the recent emergency use authorization granted by the FDA for new mRNA COVID-19 vaccines. Overall, this development not only strengthens Canada's vaccine manufacturing capabilities but also positions Moderna as a key player in the global fight against respiratory viruses, ensuring that Canada can produce essential vaccines domestically in the near future.